Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Pinealon
Also known as: Glu-Asp-Arg, EDR
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson's research group as a pineal gland bioregulator. It is proposed to have neuroprotective, geroprotective, and circadian rhythm-normalizing properties. Evidence comes primarily from in vitro studies and small Russian clinical observations. It is one of several short synthetic peptides in the Khavinson bioregulator system.
Risk Level
Low RiskDifficulty
Intermediate| Molecular Formula | C15H25N5O9 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to penetrate cell membranes and interact with DNA to regulate gene expression in neural and pineal tissue. In vitro studies show protection of neurons against oxidative stress and hypoxia. Theorized to modulate melatonin synthesis and normalize disrupted circadian signaling.
Dosing Research
Available as capsules (typically 10 mg) taken 1-2 times daily on an empty stomach for 15-30 days. Some protocols include sublingual administration. Repeat courses every 3-6 months are commonly recommended in bioregulator protocols.
Side Effects & Risks
No significant adverse effects reported in available literature. Being a very short peptide (tripeptide), it is rapidly degraded, which limits both efficacy and toxicity. No long-term safety data in controlled settings.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.